Can-Fite Granted Australian and Chinese Patents for Erectile Dysfunction Drug



Erectile dysfunction market is estimated to reach $3.2 billion by 2022

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver diseases, inflammatory diseases and sexual dysfunction, today announced that the Australian and Chinese patent offices have granted the Company a patent for the utilization of A3 adenosine receptor ligands in the treatment of sexual dysfunction, in a patent (Australian, No. 2013301125ZL, Chinese No. 2013800472970) titled, “A3 adenosine receptor ligands for use in treatment of a sexual dysfunction.”

The Company has been investigating compounds that target the A3 adenosine receptor (A3AR) and the Company’s CF602 drug candidate previously demonstrated a robust positive effect in the treatment of erectile dysfunction in preclinical studies. Can-Fite has been granted a similar patent in the U.S. for both the method for treating erectile dysfunction with different A3 adenosine receptor (A3AR) ligands and a composition of matter for allosteric compounds.
“With this strong intellectual property around the erectile dysfunction indication, we are actively looking for a partner that will help us with the clinical development and marketing approval for this important indication. We believe that this approach in treating erectile dysfunction has the potential to supply the patients with an efficacious and safe drug,” stated Can-Fite CEO Dr. Pnina Fishman

Grand View Research Inc. estimates that the value of the erectile dysfunction therapeutic market will reach approximately $3.2 billion by 2022.

For more information please visit

Share this Page: